Royalty Pharma RPRX Insider Ownership

Updated Oct 10, 2026

Over the past year, RPRX insiders sold $92.82 million of stock (2.05Mn shares) on the open market and bought none.

• A count shows 5 insiders selling RPRX stock on the open market over the past 12 months and none buying.
• Terrance P. Coyne (EVP & CFO) was RPRX's largest open-market seller in the past 12 months, with $38.96 million of sales (910.4K shares); the latest was on August 13, 2026.
• The latest open-market trade on record is a sale of 4.13K shares for $235,595 by Marshall Urist (EVP, Research & Investments) on October 5, 2026.
• Outside the open market, Royalty Pharma insiders received 530.19K shares in stock awards, acquired 160K shares through option exercises and conversions and gave away 16.8K shares as gifts over the past 12 months.
• Per Business Quant data, Royalty Pharma insiders hold 35.24Mn shares in total based on their latest Form 4 filings, down 0.47% from 35.41Mn shares at the end of Q2 2026 and down 11.08% from 39.63Mn shares at the end of Q3 2025.
• By type of ownership, RPRX insiders hold 5.51% of their shares directly (1.94Mn shares) and 94.49% indirectly (33.3Mn shares).
• The insider holdings in Royalty Pharma belong to 15 insiders who have reported on Form 4 within the past two years.
• Royalty Pharma's three largest insider shareholders, based on their latest Form 4 filings, are Pablo G. Legorreta (CEO, Chairman of the Board, 27.15Mn shares), George W. Lloyd (EVP, Investments & CLO, 2.72Mn shares) and Terrance P. Coyne (EVP & CFO, 1.81Mn shares).
• The holding of Pablo G. Legorreta makes up 77.04% of all shares held by Royalty Pharma insiders.
• Institutions accounted for 82.34% of RPRX's outstanding shares in Q2 2026.
• In the past year, 13 insiders of Royalty Pharma submitted 67 Form 4 filings reporting trades, awards or other transactions.
• Insider figures for RPRX include Form 4 filings through October 5, 2026.